Stolper Co Boosts Stock Position in Pfizer Inc. $PFE

Stolper Co grew its position in Pfizer Inc. (NYSE:PFE) by 92.4% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 63,611 shares of the biopharmaceutical company’s stock after purchasing an additional 30,553 shares during the period. Stolper Co’s holdings in Pfizer were worth $1,532,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Godfrey Financial Associates Inc. acquired a new position in Pfizer in the 4th quarter worth approximately $26,000. Keb Asset Management LLC acquired a new stake in Pfizer during the 2nd quarter valued at approximately $26,000. HFM Investment Advisors LLC boosted its holdings in shares of Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 427 shares during the last quarter. Evolution Wealth Management Inc. boosted its holdings in shares of Pfizer by 132.2% in the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 566 shares during the last quarter. Finally, Abound Financial LLC acquired a new stake in shares of Pfizer in the fourth quarter worth $31,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. BMO Capital Markets decreased their target price on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research report on Monday, July 13th. HSBC downgraded Pfizer from a “buy” rating to a “hold” rating and cut their price target for the stock from $32.00 to $28.00 in a research report on Monday, July 6th. Bank of America decreased their price objective on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Friday, July 10th. CICC Research assumed coverage on Pfizer in a research note on Thursday, April 16th. They issued an “outperform” rating and a $33.00 target price on the stock. Finally, Wall Street Zen raised Pfizer from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $28.28.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer CEO Albert Bourla purchased approximately $1 million of company stock, adding 38,000 shares. The insider purchase may signal management’s confidence that the shares are undervalued. Pfizer CEO Buys $1 Million of Stock
• Positive Sentiment: Pfizer’s second-quarter results exceeded expectations, and management modestly raised 2026 revenue guidance to $60.5 billion-$62.5 billion. Analysts also highlighted stable core operations, strength from acquired brands and recent launches, and momentum in the non-COVID business. 5 Insightful Analyst Questions From Pfizer’s Q2 Earnings Call
• Positive Sentiment: Positive Phase 3 results for LITFULO in nonsegmental vitiligo strengthen Pfizer’s immunology pipeline and support the company’s effort to replace declining COVID-related revenue with newer products. Pfizer’s Higher 2026 Guidance and LITFULO Trial Results
• Positive Sentiment: Recent coverage points to growing investor interest in Pfizer’s launches, acquisitions and pipeline as potential drivers of longer-term growth, particularly from 2029 onward. Will Pfizer’s Non-COVID Portfolio Drive Its Next Phase of Growth?
• Neutral Sentiment: Analysts remain broadly focused on Pfizer’s valuation and earnings outlook; Erste Group raised its 2026 EPS estimate to $2.95 from $2.92, close to the approximately $2.98 consensus. Analysts Offer Insights on Healthcare Companies
• Negative Sentiment: Pfizer discontinued hemophilia gene therapy BEQVEZ as the commercial market contracts and physicians demand longer-term efficacy data, removing a potential growth contributor. Gene Therapy Remains Top-of-Mind in Hemophilia
• Negative Sentiment: Pfizer agreed to a $44 million class-action settlement related to Chantix safety-disclosure claims. The financial charge is manageable relative to Pfizer’s size but highlights continuing litigation exposure. Pfizer Agreed to a $44 Million Chantix Settlement
• Negative Sentiment: Arbutus filed additional patent-enforcement lawsuits against Pfizer and BioNTech concerning lipid nanoparticle technology, creating another potential legal overhang tied to COVID vaccine intellectual property. Arbutus Reports Second-Quarter Results

Pfizer Price Performance

Pfizer stock opened at $26.80 on Friday. The stock has a market capitalization of $152.77 billion, a P/E ratio of 35.27 and a beta of 0.34. The company’s fifty day moving average price is $25.11 and its 200 day moving average price is $26.19. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. Pfizer Inc. has a 1 year low of $23.58 and a 1 year high of $28.75.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.68 by $0.09. The business had revenue of $15.03 billion for the quarter, compared to the consensus estimate of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company’s revenue was up 2.6% compared to the same quarter last year. During the same period last year, the firm posted $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, equities research analysts anticipate that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.4%. The ex-dividend date is Friday, July 24th. Pfizer’s payout ratio is presently 226.32%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.